Watch More Highlights
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses data that show rigosertib and azacitidine may provide a potential new first-line treatment for patients with high-risk myelodysplastic syndrome (Abstract 4268).
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses data that show rigosertib and azacitidine may provide a potential new first-line treatment for patients with high-risk myelodysplastic syndrome (Abstract 4268).